Chemaityelly, Hiam; Harfouche, Manale; Blondeel, Karel; Matsaseng, Thabo Christopher; Kiarie, James; Toskin, Igor; Abu-Raddad, Laith J; (2019) Global epidemiology of Neisseria gonorrhoeae in infertile populations: protocol for a systematic review. BMJ open, 9 (5). e025808-. ISSN 2044-6055
DOI: https://doi.org/10.1136/bmjopen-2018-025808

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4653241/

DOI: https://doi.org/10.1136/bmjopen-2018-025808

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
Global epidemiology of Neisseria gonorrhoeae in infertile populations: protocol for a systematic review

Hiam Chemaitelly,1 Manale Harfouche,1 Karel Blondeel,2,3 Thabo Christopher Matsaseng,2 James Kiarie,2 Igor Toskin,2 Laith J Abu-Raddad4,1,5

ABSTRACT

Introduction A key target of the WHO’s ‘Global Health Sector Strategy on sexually transmitted infections, 2016–2021’ is achieving 90% reduction in Neisseria gonorrhoeae (gonorrhoea for short) incidence globally by 2030. Though untreated, gonorrhoea has been linked to infertility, the epidemiology of this infection in infertile populations remains poorly understood and somewhat a neglected area of reproductive health. Our proposed systematic review aims to fill this gap by characterising comprehensively gonorrhoea infection in infertile populations globally.

Methods and analysis All available studies of gonorrhoea infection in infertile populations, including infertility clinic attendees, will be systematically reviewed informed by Cochrane Collaboration guidelines. Findings will be reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data sources will be searched using broad index terms exploded to cover all subheadings and free text terms with no language or year restriction. Any epidemiological measure in infertile populations based on primary data will be eligible for inclusion. Measures based on different assay types will be extracted as separate studies for different analyses. Only one biospecimen type per assay type will be considered based on a predefined priority order. Samples including fewer than 10 participants or assessing infection in the upper genital tract will be excluded. Quality assessments will be conducted for all measures included in the review. Meta-analyses will be implemented using DerSimonian-Laird random effect models to estimate the mean prevalence of gonorrhoea in infertile populations globally, and stratified by WHO region, assay type, sex, infertility type, infertility diagnosis, among other factors. Detailed heterogeneity assessment will be performed, and potential sources of between-study heterogeneity will be explored using meta-regression. Review will be conducted from 26 March 2018 to 28 July 2019.

Ethics and dissemination An institutional review board clearance is not required as all data are publicly available. The findings will be disseminated through a peer-reviewed publication and international scientific meetings/workshops with key stakeholders.

PROSPERO registration number CRD42018102934

INTRODUCTION

Gonorrhoea is a common sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. In 2012, the World Health Organization (WHO) estimated the rate of new gonorrhoea infections globally at 19 per 1000 women and 24 per 1000 men, suggesting the exposure of well over 75 million individuals to the infection every year.

A large fraction of these infections are asymptomatic, thus evading detection and treatment, and increasing the risk for serious reproductive health outcomes such as cervicitis, pelvic inflammatory disease and subsequently infertility in women, and epididymitis, epididymo-orchitis, chronic prostatitis and subsequently infertility in men. Infertility is estimated to affect close to 2% of reproductive age women with no prior live birth and over 10% of reproductive age women with earlier successful deliveries. Data on the prevalence of infertility among men are scarce. Available regional estimates are in the range of 2.5%–12%, based on survey data.
among women and assuming that 20%-30% of female infertility is attributed to a male factor.7

Despite their health, social and economic implications,13 STIs and infertility have for long languished at the bottom on health policy agendas. Recently, within the framework of the United Nations’ Sustainable Development Goal 3 of ‘ensuring healthy lives and promoting the well-being for all’,10 the WHO has formulated the ‘Global Health Sector Strategy on STIs, 2016–2021’.11 The strategy’s goal is to end STI epidemics as a public health concern by 2030.11 A key target is achieving, by 2030, 90% reduction in N. gonorrhoeae incidence.11 Five strategic directions/actions are proposed to guide countries’ progress towards set targets; the first is to understand the STI epidemic and STI burden including infertility as a basis for advocacy, political commitment, national planning, resource mobilisation and allocation, implementation and programme improvement.11

Against this background, our proposed systematic review aims to characterise comprehensively the global epidemiology of gonorrhoea infection in infertile populations defined broadly to also include partners/infertility clinic attendees. Our specific objectives are (1) to conduct a global systematic review and synthesis of evidence of gonorrhoea infection prevalence in infertile populations, (2) to generate estimates for the pooled mean prevalence of gonorrhoea in infertile populations globally, as well as stratified by WHO region, type of assay, sex, infertility type and infertility diagnosis among other relevant key factors and (3) to identify sources of between-study heterogeneity and quantify their contribution to the variability in gonorrhoea prevalence.

Strictly speaking, this study does not aim to investigate the causal link between gonorrhoea infection and infertility. Investigating such direct causal link has proved difficult, as prospective studies are not possible, for ethical reasons, given that gonorrhoea is a curable infection. Our study thus provides only indirect suggestive evidence for a potential link between gonorrhoea infection and infertility. However, current gonorrhoea infection is often predictive of past exposure to the infection and vice versa.12–14 Most these exposures are asymptomatic and thus of unknown duration and persistence.

METHODS

The development of this protocol was informed by the Cochrane Collaboration guidelines,15 with section items reported based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) guidelines.16 The checklist for PRISMA-P can be found in table 1. The timeline for conducting the review of the literature is from the 26th of March 2018 to the 28th of July 2019.

Review questions

The research questions are: What is the scope of evidence for gonorrhoea infection among infertile populations? What are the pooled mean gonorrhoea infection levels among infertile populations globally, and do these estimates vary by WHO region, assay type, sex, infertility type and infertility diagnosis among other relevant factors? What sources contribute to the heterogeneity in gonorrhoea prevalence among infertile populations?

Data sources and search strategy

We will search the global literature by surveying PubMed, Embase and WHO Index Medicus databases using broad index terms, that is MeSH/Emtree terms exploded to cover all subheadings, as well as relevant free text terms for ‘gonorrhoea’, ‘neisseria gonorrhoeae’, ‘pelvic inflammatory disease’, ‘gonococcus’, ‘gonococci’, ‘gonococcal’, ‘epididymitis’, ‘orchitis’, ‘seminal vesicle disease’ and ‘seminal vasculitis’ matched with ‘infertility’, ‘fertility’ and ‘assisted reproductive techniques/infertility therapy’, with no language or year restriction. Our search strategy was drafted to capture any study among infertile populations that could include gonorrhoea as a primary or secondary outcome. Epidemiology terms restricting the search to outcomes of interest such as ‘incidence’ or ‘prevalence’ were not used to ensure the search comprehensiveness. Our detailed search strategy can be found in box 1. This initial search was conducted on the 8th of May 2018 and will be updated prior to manuscript publication.

The bibliography lists of all articles included in the review and all relevant reviews of literature will be further hand searched to avoid missing any articles with relevant information.

Eligibility criteria
Any document reporting a measure of gonorrhoea prevalence in infertile populations based on primary data will be eligible for inclusion in the review. Our definition of infertile populations is broad and includes men and/or women undergoing any infertility evaluation or treatment, that is, infertility clinic attendees and their partners. No restrictions based on study setting, time frame or language will be applied. Our exclusion criteria cover case reports, case series, editorials, commentaries, qualitative studies, literature reviews whose bibliography lists will still be hand searched for any additional articles that can be potentially relevant, studies in populations exposed to voluntary sterilisation, studies based on self-reported exposure to gonorrhoea, studies assessing gonorrhoea in samples of less than 10 participants as these have too small of a sample to provide a meaningful measure of prevalence and studies assessing the infection in tissue samples from the upper genital tract given our interest in current urogenital infection with gonorrhoea.

Study outcomes and prioritisation

Our outcome of interest includes any gonorrhoea prevalence measure that is the number of existing current urogenital gonorrhoea infections or gonococcal antibodies identified among an infertile population.
Table 1 Preceding reporting items for systematic review and meta-analysis protocols checklist16

| Section and topic                  | Item no | Checklist item                                                                 | Addressed in page |
|-----------------------------------|---------|---------------------------------------------------------------------------------|-------------------|
| Administrative information        |         |                                                                                  |                   |
| Title                             | 1a      | Identify the report as a protocol of a systematic review                         | 1                 |
| Identification                    | 1b      | If the protocol is for an update of a previous systematic review, identify as such | NA                |
| Registration                      | 2       | If registered, provide the name of the registry (such as PROSPERO) and registration number | 3, 12             |
| Authors                           |         |                                                                                  |                   |
| Contact                           | 3a      | Provide name, institutional affiliation, email address of all protocol authors; provide physical mailing address of corresponding author | 1                 |
| Contributions                     | 3b      | Describe contributions of protocol authors and identify the guarantor of the review | 1, 15             |
| Amendments                        | 4       | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | NA                |
| Support                           |         |                                                                                  |                   |
| Sources                           | 5a      | Indicate sources of financial or other support for the review                    | 15                |
| Sponsor                           | 5b      | Provide name for the review funder and/or sponsor                                | 15                |
| Role of sponsor or funder         | 5c      | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | 15                |
| Introduction                      |         |                                                                                  |                   |
| Rationale                         | 6       | Describe the rationale for the review in the context of what is already known     | 4–5               |
| Objectives                        | 7       | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators and outcomes (PICO) | 5–6               |
| Methods                           |         |                                                                                  |                   |
| Eligibility criteria              | 8       | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 6–7               |
| Information sources               | 9       | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 6                 |
| Search strategy                   | 10      | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 6 & box 1         |
| Study records                     |         |                                                                                  |                   |
| Data management                   | 11a     | Describe the mechanism(s) that will be used to manage records and data throughout the review | 7–8               |
| Selection process                 | 11b     | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 8                 |
| Data collection process           | 11c     | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 8–9               |
| Data items                        | 12      | List and define all variables for which data will be sought (such as PICO items, funding sources), any preplanned data assumptions and simplifications | 8–9               |
### Table 1  Continued

| Section and topic               | Item no | Checklist item                                                                 | Addressed in page |
|--------------------------------|---------|---------------------------------------------------------------------------------|-------------------|
| **Outcomes and prioritisation** | 13      | List and define all outcomes for which data will be sought, including prioritisation of main and additional outcomes, with rationale | 7                 |
| **Risk of bias in individual studies** | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level or both; state how this information will be used in data synthesis | 9–10              |
| **Data synthesis**             | 15a     | Describe criteria under which study data will be quantitatively synthesised      | 10                |
|                                | 15b     | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall’s τ)   | 10–11             |
|                                | 15c     | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 11                |
|                                | 15d     | If quantitative synthesis is not appropriate, describe the type of summary planned | NA                |
| **Metabias(es)**               | 16      | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | 11                |
| **Confidence in cumulative evidence** | 17 | Describe how the strength of the body of evidence will be assessed | 9–10              |

NA, not applicable; PICO, participants, interventions, comparators and outcomes; PROSPERO, International Prospective Register of Systematic Reviews.
first screening stage, articles will be coded 1 ‘relevant’ if an outcome of interest is reported in the abstract, 2 ‘potentially relevant’ if an outcome of interest is not reported in the abstract but could be included in the full-text and 0 ‘not relevant’ if otherwise. Double screening for a fraction of the articles (25%) will be performed by another coauthor (MH), and discrepancies will be discussed among authors. Full texts of articles identified as ‘relevant’ or ‘potentially relevant’ will be retrieved for further screening. For this systematic review, the term ‘report’ will be used to refer to a research document/article that includes one or more outcome measures of interest (here, gonorrhoea incidence or prevalence), while the term ‘study’ will be used to refer to details related to a specific outcome measure in a specific population. Duplicate study findings will be considered only once; however, all reports of a study will be retained during screening, and eventually the most complete data for each outcome will be extracted from wherever it is most completely reported.

Data extraction and management

Data from articles identified as relevant during the full-text screening stage will be extracted by HC into a statistical software program. The following information will be extracted: author(s), publication year, full citation, country, WHO region, year of data collection start and end, study site, study design, sampling methodology, biological specimen type, sample size, study population and its characteristics (sex, age, infertility type, infertility diagnosis, presence of urogenital signs and symptoms), sample size of tested population, number of participants positive for gonorrhoea infection and type of assay used for gonorrhoea infection ascertainment. In addition to the overall gonorrhoea measure, reported stratified measures will be extracted whenever 10 or more individuals have been included per stratum. Double extraction will be performed by MH, and discrepancies will be settled by consensus or by contacting the authors. Data extraction for articles in foreign languages will be performed by native speakers as available.

Risk of bias assessment

A risk of bias assessment (ROB) for each gonorrhoea study included in the review will be conducted and informed by the Cochrane approach and existing studies. Each study will be rated as having ‘low’ versus ‘high’ ROB on four quality domains assessing (1) the validity of the infertility definition (follows WHO definition that is failure to conceive after at least 1 year of regular unprotected intercourse vs otherwise), (2) the lack of exposure to antimicrobials for at least 1 week prior to the collection of biological samples (ascertained vs otherwise), (3) consistency in the assay used for infection ascertainment (same assay used for testing all participants vs otherwise) and (4) the response rate (≥80% vs <80%). Studies with missing information for any of the domains will be considered as having ‘unclear’ ROB for that specific domain. The precision of measures will be determined based on the sample size of the population tested. A study will be considered of ‘high’ precision if its original sample included a minimum of 100 tests for gonorrhoea infection.

In addition to reporting findings of the ROB assessment for individual studies, confidence in the body of evidence will be assessed by reporting the fraction of studies with low (or high) ROB in, respectively, at least one, two, three or all four quality domain(s).

The impact of ROB and precision domains on observed prevalence will be investigated through forest plots, meta-analyses and meta-regressions. Results for the ROB and precision assessments will be carefully considered in the interpretation of review findings.

Data synthesis and analysis

Gonorrhoea studies based on the overall sample will be reported in a table format along with key information pertaining to each study. The scope of evidence will be described by conducting descriptive analyses (ranges and medians) on the extracted data. Forest plots will be also produced to visualise prevalence measures and their 95% CIs stratified by key study and population characteristics (WHO region, assay type, sex, infertility type, infertility diagnosis, median year of data collection, sample size/precision, presence of urogenital signs and symptoms and ROB domains).

The global and regional pooled estimates for the mean gonorrhoea prevalence and their associated 95% confidence intervals (CIs) will be then calculated using meta-analysis. Here, the prevalence measure for the overall study sample (for example, gonorrhoea prevalence in women) will be replaced by stratified measures (for example, gonorrhoea prevalence in women by infertility diagnosis), whenever possible. For each study, only one stratification will be selected based on the following order of priority: country, sex, infertility diagnosis, infertility type, age and year of data collection. The variances of selected studies will be stabilised using a Freeman–Tukey double arcsine square-root transformation. Additional meta-analyses will be implemented to estimate the pooled mean gonorrhoea prevalence stratified by assay type, sex, infertility type and infertility diagnosis among other factors (such as ROB and precision domains).

Heterogeneity across studies will be described by reporting, for each meta-analysis: the Cochran’s Q statistic, a measure that assesses the existence of heterogeneity across studies; $I^2$ a measure that quantifies the magnitude of between-study variation due to true differences in effect size across studies and the prediction interval, a measure that estimates the 95% interval of the distribution of true effect sizes.
Metaregression analyses will be conducted to explore potential sources of between-study heterogeneity. Univariable analyses will be first implemented to examine the association of key a priori predictors (WHO region, assay type, sex, infertility type, infertility diagnosis, median year of data collection, sample size/precision (small-study effect), presence of urogenital signs and symptoms and ROB domains) with gonorrhoea prevalence. Any association with p value $\leq 0.1$ in univariable analyses will be eligible for inclusion in the multivariable model. Here, predictors with a p value $\leq 0.05$ will be retained in the final model. Adjusted odds ratios and 95% CIs will be reported.

Sensitivity analyses will be considered based on preliminary results.

Patient and public involvement
By design, no patients and/or public are involved in the proposed study.

DISCUSSION
The proposed systematic review is, to our knowledge, the first to characterise comprehensively the epidemiology of gonorrhoea infection in fertile populations. Our study is timely and will inform efforts attending to the WHO ‘Global Health Sector Strategy on STIs, 2016–2021’, particularly to the key target of reducing gonorrhoea incidence globally by 90% by 2050.14 Our study will also shed light on the role of STI epidemiology in infertility, a condition with severe social and economic implications69 that has been for long a largely neglected area of reproductive health. The ultimate aim of this work is to provide the evidence necessary to inform public health research, policy and the adequate resource allocation and prioritisation.

Contributors
The proposed study was conceived by LJA-R and designed by HC and LJA-R. HC developed the search strategy with input from LJA-R, IF, KB, JK and TCM. Literature searches and duplicate screening was conducted by HC. Strategies and LJA-R. HC developed the search strategy with input from LJA-R, IT, KB, JK and TCM. Literature searches and duplicate screening was conducted by HC. Strategies

Funding
This publication was made possible by funding from the WHO. This work was also funded by the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, a cospersoned programme executed by the WHO.

Disclaimer
TCM, JK and IT are staff members of the WHO. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the views, decisions or policies of the WHO.

Competing interests
None declared.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References
1. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015;10:e0143304.
2. Centers for Disease Control and Prevention. Gonorrhea–CDC Fact Sheet (Detailed version). 2017 https://www.cdc.gov/std/gonorrhea/stdfact gonorrhea-detailed.htm (Accessed 18 Dec 2017).
3. Ness RB, Markovic N, Carlson CL, et al. Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Fertil Steril 1997;68:295–13.
4. Ochsendorf FR. Sexually transmitted infections: impact on male fertility. Andrology 2008;40;72–5.
5. Mascalzehens MN, Flaxman SR, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 2012;9:e1001356.
6. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update 2015;21:411–26.
7. Agarwal A, Mulgund A, Hamad A, et al. A unique view on male infertility around the globe. Reproductive biology and endocrinology: RB&E 2015;13:37.
8. Cui W. Mother or nothing: the agony of infertility. Bull World Health Organ 2010;88:881–2.
9. Katz P, Showstack J, Smith JF, et al. Costs of infertility treatment: results from an 18-month prospective cohort study. Fertil Steril 2011;95:915–21.
10. United Nations General Assembly. Transforming our world: the 2030 Agenda for Sustainable Development, 2015.
11. World Health Organization. Global health sector strategy on sexually transmitted infections, 2016-2021, Geneva, Switzerland: World Health Organization, 2016.
12. Fowler T, Caley M, Johal R, et al. Previous history of gonococcal infection as a risk factor in patients presenting with gonorrhoea. Int J STD AIDS 2010;21:97–101.
13. Rosenfeld CB, Worowski KA, Berman S, et al. Repeat infection with chlamydia and gonorrhoea among females: a systematic review of the literature. Sex Transm Dis 2009;36:478–88.
14. Walker CK, Sweet RL. Gonorrhoea infection in women: prevalence, effects, screening, and management. Int J Womens Health 2011;3:197–206.
15. Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell, 2008.
16. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
17. Khadr L, Harfouche M, Omoni R, et al. The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2018.
18. Muntaz GR, Weiss HA, Thomas SL, et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med 2014;11:e1001663.
19. Chaabane S, Harfouche M, Chemaitelly H, et al. Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. Sci Rep 2019;9:1136.
20. Koyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep 2018;8:1661.
21. Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals of Mathematical Statistics 1950;21:607–11.
22. Miller JJ. The inverse of the Freeman – tukey double arcsine transformation. The American Statistician 1978;32.
23. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974–8.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
25. Michael Borenstein LVH, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester, U.K: John Wiley & Sons, 2009.